Hepatocellular study by using long term doses of diclofenac sodium (NSAIDs) in mice models

SARFARAZ H., FARAH K. and N. GANESH

Jawaharlal Cancer Hospital and Research Centre, Idgah hills, Bhopal - 4620 001 (India)

(Received: October 14, 2007; Accepted: November 24, 2007)

ABSTRACT

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID), which has been associated with severe idiosyncratic hepatotoxicity. In this study we investigated the effects of different doses of diclofenac sodium on liver tissues.

Key words: Non-steroidal anti-inflammatory drug (NSAIDs), Diclofenac sodium, Swiss albino, hepatic cells.

INTRODUCTION

Non-steroidal anti-inflammatory drugs (NSAIDs) are the center piece of pharmacotherapy for most rheumatological disorders and are used in large numbers as analgesics and antipyretics1-4. Diclofenac and particularly sulindac are reported to be more commonly associated with hepatotoxicity5-9. Diclofenac sodium causes a rise in liver function, and has also been reported to cause hepatitis10-12. The exact mechanism is not known but it is probably related to the decrease in the fatty acid entering the cell or released from the cell16. The literature has continued to broaden our understanding of the potential toxic events associated with the use of these agents14-15. These products have some potent biological activities affecting cell function in every organ. The high levels of NSAIDs also inhibit the activities of various enzymes, the proteoglycan synthesis from chondrocytes, the ionic exchange rate and the process depending on prostanlandins14-15. Diclofenac is extremely metabolized in the liver17. Therefore, the present study aimed to investigate only the hepatotoxic and nephrotoxic effects of increasing doses of diclofenac of liver tissue in mice. Based on several observations, a regular intake of NSAIDs is associated with a decreased incidence of various type of cancers (Suh O, Mettlin C, et al. Cancer 1993; 72: 1171-1177) and (Rosenberg L., et al, J Natl. Cancer Inst. 1991; 83: 355-358). The experimental results suggest that the toxic effect of diclofenac on hepatocytes may be caused by drug-induced mitochondria impairment, together with a futile consumption of NADPH. (Roque Bort et al.,) Careful patient monitoring is advised and prompt discontinuation of the drug is suggested when signs or symptoms of liver disease develop (S.M. Helfgott et al.,) Keeping in view of the previous study done by these above references shown diclofenac caused significantly higher cell death at elevated dose, so we have put our efforts to rule out the toxic menace of diclofenac in rodent's (Swiss albino).

MATERIAL AND METHODS

Swiss albino mice. Age/Weight/Size: 2-3 month’s, 30 Grams to 35 Grams-Male and Female both). Diclofenac sodium tablets dissolved is double distilled water in different concentrations for short and long term administration was divided into following groups: (High dose-10mg/Kg for One day only, Medium dose - 1mg/Kg for 10 days only,
Low-0.3mg/Kg for 30 days, Very low-0.1mg/Kg for 30 days, Control-Water without drug). Diclofenac sodium was administrated orally with different concentration of drug to separate groups from having 4-animals for each group in, low doses to high dose. Experimental mice were sacrificed by cervical dislocation. The livers were removed, blotter dry on filter paper and weighed. Sections from the left and right lobe of the liver were fixed in 10% buffered formalin for 24 hours, dehydrated in graded ethanol solutions, embedded in paraffin, sectioned at 5micron and stained with haematoxylin and eosin. The slides were now mounted in DPX.

**Observation**

Mice were treated with different concentrations of Diclofenac sodium (0.1 mg/kg-10 mg/kg) for different time duration (1 days-30 days), after that they were dissected out, Liver portion was made T.S. and observed under binocular

---

**Fig. 1:** Histologic section of mice Liver from the control group. Normal lobular structures (NLs), Normal Hepatocytes (NH). (Hematoxylin-eosin, x 100).

**Fig. 2:** Histologic section of mice Liver from the (0.1mg/kg) diclofenac sodium administered group. Hypocromic cells (Hp), Hepatocytes with Pyknotic nucleus and Eosinophilic cytoplasm (HpEc) (Hematoxylin-eosin, x 100).

**Fig. 3:** Histologic section of mice Liver from the (1mg/kg) diclofenac sodium administered group. Parenchymal cell Necrosis (PcN), Sinusoidal dilatations (SD), Hepatocytes with Pyknotic nucleus and Eosinophilic cytoplasm (HpEc) (Hematoxylin-eosin, x 100).

**Fig. 4:** Histologic section of mice Liver from the (10mg/kg) diclofenac sodium administered group. Sinusoidal dilatations (SD), Hepatocytes with Pyknotic nucleus and Eosinophilic cytoplasm (HpEc), Enlargement in Hepatocytes (EH) (Hematoxylin-eosin, x 10)
microscope. Histological examination of the liver tissues in the control group revealed no significant dermination from the normal histological structure Fig. 1-5. The Diclofenac sodium treatments groups significantly affected the cellular morphology in the histological structure of the Liver, especially hepatocytes.

**RESULTS AND DISCUSSION**

In the present study, dose-dependent changes were seen in liver tissue samples. In the first diclofenac group, these changes were very mild and reversible. Similar changes were also seen in the second diclofenac group. In the third diclofenac group the changes seen compared with those in the first diclofenac group were aggressive and common: there were hepatocyte necrosis. Parenchymal cell Necrosis mild fibrous tissue proliferation and interstitial and periportal inflammation, Hepatocytes with Pyknotic nucleus and Eosinophilic cytoplasm which indicate acute hepatitis. These findings suggest that a high dose of diclofenac sodium causes irreversible cell death, as well as cell demage, fibrous tissue proliferation and acute hepatitis12-13. The association of NSAIDs with liver diseases is poorly documented.

**REFERENCES**


